Navigation Links
Affinity in Medical Technology

Anavex presents neuroprotective effects of Anavex 1-41 at the International Conference on Alzheimer's Disease 2008

... drug candidates demonstrate high, non-exclusive affinity for sigma receptors, which are involved in ... drug candidates exhibit high, non-exclusive affinity for sigma receptors with strong evidence for ... lead drug candidates exhibit high, non-exclusive affinity for sigma receptors with strong evidence for ...

Intra-Cellular Therapies Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders

... 5HT2A receptors with a 60-fold higher affinity for 5HT2A receptors over D2 receptors. In vivo, ... Additionally, ITI-007 was shown to have an affinity for the serotonin reuptake site, an activity ... histaminergic receptors and has a reduced affinity for adrenergic receptors relative to other ...

Dainippon Sumitomo Pharma Announces Lurasidone Phase III Data in Patients With Schizophrenia

... is a novel compound with a unique receptor-binding profile including high affinity for dopamine D(2), serotonin 5-HT(2A), 5-HT(7), 5-HT(1A), and noradrenalin alpha(2c) receptors. Lurasidone has low affinity for histamine H(1), and cholinergic M(1) receptors. About ...

RAPAFLO(TM) (silodosin) Provides Rapid and Sustained Benign Prostatic Hyperplasia (BPH) Symptom Relief in as Little as Three Days

... RAPAFLO(TM) maximizes target organ activity by binding with high affinity to the alpha (1A) receptors concentrated in the prostate. The antagonism ... in improved urine flow and a reduction in BPH symptoms. The binding affinity for the alpha (1B) receptors that cause smooth muscle in peripheral ...

Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)

... selective alpha-1 adrenergic receptor antagonist that binds with high affinity to the alpha 1a receptors concentrated in the prostate, bladder base and ... in improved urine flow and a reduction in BPH symptoms. The binding affinity for the alpha 1B receptors that regulate smooth muscle relaxation and ...

Access Pharmaceuticals Presents new Combination Data on the Company's Angiolix(R) Therapeutic Monoclonal Antibody

... antibody, Angiolix, which confirmed that Angiolix(R) binds with high affinity to the its target, lactadherin, resulting in anti-angiogenesis and ... which has considerable potential for the treatment of cancer through its affinity for a novel target, lactadherin. Lactadherin is an extracellular matrix ...

Novel Compound Shows Promise for Treatment of Alcoholism

... for alcoholism. This study indicates that compounds with a higher affinity for delta opioid receptors and reduced affinity for mu opioid receptors might be better treatment candidates than ...

Intra-Cellular Therapies Presents Preclinical Data From Schizophrenia and Sleep Maintenance Programs

... not interact with muscarinic or histaminergic receptors and has a reduced affinity for adrenergic receptors relative to other antipsychotic drugs and ... and other deleterious side effects. In addition, the wide separation of affinity at 5HT2A and D2 receptors may allow for administration of the appropriate ...

Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models

... or moxifloxacin to a bisphosphonate via cleavable linkers. The affinity of the prodrugs for bone was determined by exposing individual compounds ... parent fluoroquinolone at various rates. In this in vitro study, the high affinity displayed by the compounds for bone powder and their ability to regenerate ...

CoAxia, Inc. Announces $21.5M Series D Financing

... completion of a $21.5M Series D financing. The round was led by Sofinnova Partners with participation from all previous major investors including affinity Capital Management, Baird Venture Partners, Canaan Ventures Partners, Johnson and Johnson Development Corporation, and Prism Ventureworks. In ...

MacroGenics and Lilly Achieve Targeted Patient Enrollment in PROTEGE, a Global Phase 2/3 Clinical Trial of Teplizumab in Type 1 Diabetes

... product development. The company's product development efforts leverage three proprietary technology platforms: (1) cancer stem-like cells; (2) Dual affinity Re-Targeting (DART), which allows the company to incorporate multiple specificities within a single molecule; and (3) Fc optimization, which enhances ...

Study Demonstrating Lurasidone Is Effective in Patients With Schizophrenia Published in The Journal of Clinical Psychiatry

... high affinities for dopamine D(2), serotonin 5-HT(7), 5-HT(2A), 5-HT(1A), and noradrenaline alpha(2C) receptors. Lurasidone exhibits little or no affinity for histamine H(1) or acetylcholine M(1) receptors. About Schizophrenia Schizophrenia is a chronic, disabling and serious medical illness ...

Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients

... of the leading androgen receptor antagonist, bicalutamide. Specifically, MDV3100: blocks the androgen receptor with greater binding affinity than bicalutamide; impairs nuclear translocation and blocks DNA binding of the androgen receptor, one of the key steps required for ...

Video: Partnership Unites UCB with Consumer Product Innovator OXO(R)

... events (5%). About CIMZIA (R) CIMZIA (R) is the only PEGylated anti-TNF (Tumour Necrosis Factor). Cimzia (R) has a high affinity for human TNF-alpha, selectively neutralising the pathophysiological effects of TNF-alpha. Over the past decade, TNF-alpha has emerged as a major ...

Corgenix, Tulane Announce Award of NIH Grant Extending Hemorrhagic Fever Virus Product Development Program

... emerging biotechnology company with a proprietary biopharmaceutical drug pipeline and platform technology for human monoclonal antibody selection and affinity maturation. The company's contract division has developed over 150 recombinant proteins in multiple expression systems including 12 biologic drugs in ...

Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion

... VEGF Trap-Eye is a specific blocker of VEGF-A and PlGF that has been demonstrated in preclinical models to bind these growth factors with greater affinity than their natural receptors. Regeneron and Bayer HealthCare are collaborating on the global development of VEGF Trap-Eye for the treatment of ...

Intellect Neurosciences, Inc. Announces Independent Studies on Copper Binding Properties of its Lead Candidate OXIGON(TM)

... a close structural homolog of OXIGON(TM). The interaction was shown to involve four specific amino acids, which now are known to comprise the high affinity copper binding site in the beta amyloid protein. Professor Hong's findings provide the missing link to explain the biochemical significance of these ...

Atritech to Participate in Late-Breaking Clinical Trial Presentation at American College of Cardiology Meeting

... Atritech include SplitRock Partners, Prism Venture Partners, Tullis-Dickerson Partners, , The Vector Group, Thoma Cressey Funds, SightLine Funds and affinity Capital. For more information, visit http://www.atritech.net . ...

Pieris Reports Development Progress for Anticalin(R) PRS-050, a Next Generation VEGF Antagonist

... proteins derived from the scaffold of natural human lipocalins. Anticalins are selected to have prescribed binding properties with selectivity and affinity fundamentally similar to that of monoclonal antibodies. Being human in origin, Anticalins are predicted to have minimal immunogenicity in man. ...

Intra-Cellular Therapies Announces Successful Outcome of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia

... incurring high levels of dopamine antagonism that cause motor disturbances and other deleterious side effects. In addition, the wide separation of affinity at 5HT2A and D2 receptors may allow for administration of the appropriate amount of dopamine modulation for antipsychotic maintenance therapy and the ...

A Window Into Parkinson's Disease

... of proteins they produce, or their "translational profile." The new method discovered by Greengard, Heiman, and colleagues, Translating Ribosome affinity Purification (TRAP), reveals translational profiles in cells by isolating the genetic messages as they pass through the protein production factories ...

Raptor Pharmaceuticals Provides Update on Targeting Platforms

... The collaborative research with Brigham and Women's Hospital focuses on RAP sequence variants engineered for improved binding affinity and enhanced stability in complex with receptors. Under terms of the agreement, the Blacklow Laboratory, a substantial contributor to the study of ...

CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years

... for damaging the joint. About CIMZIA(R) (certolizumab pegol) CIMZIA is the only PEGylated anti-TNF (Tumor Necrosis Factor). CIMZIA has a high affinity for human TNF-alpha, selectively neutralizing the pathophysiological effects of TNF-alpha. Over the past decade, TNF-alpha has emerged as a major ...

CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients

... anti-TNFa (Tumour Necrosis Factor). CIMZIA is an effective, rapid-acting and long lasting treatment option for people with RA. CIMZIA has a high affinity for human TNF-alpha, selectively neutralizing the pathophysiological effects of TNF-alpha. Over the past decade, TNF-alpha has emerged as a major ...

CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients

... anti-TNFa (Tumour Necrosis Factor). CIMZIA is an effective, rapid-acting and long lasting treatment option for people with RA. CIMZIA has a high affinity for human TNF-alpha, selectively neutralizing the pathophysiological effects of TNF-alpha. Over the past decade, TNF-alpha has emerged as a major ...

Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation

... this technology broadly with over 70 revenue generating licenses and collaborations for therapeutic discovery, as well as in non-core areas such as affinity separations, diagnostic imaging, and research reagents. Dyax Disclaimer This press release contains forward-looking statements, ...

Access Pharmaceuticals Presents New Data on the Company's Angiolix(R) Therapeutic Monoclonal Antibody

... About Angiolix: Angiolix is a novel humanized monoclonal antibody which has considerable potential for the treatment of cancer through its affinity for a novel target, lactadherin. Lactadherin is an extracellular matrix protein that is released by numerous types of tumor cells, including most ...

Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies

... as a cancer therapeutic agent." "HAAH is an excellent target for monoclonal antibody cancer therapeutics, and we have developed several high affinity antibodies against HAAH with good promise as cancer therapeutics," commented K. Dane Wittrup, Ph.D., Carbon P. Dubbs Professor of Chemical ...

Addrenex Pharmaceuticals' New Hires Further Company Goal to Identify New Drugs for Adrenergic Regulation

... and other potential indications. Bream will work with University of Nebraska scientists to further analyze various compounds for their affinity to alpha-2 adrenergic receptors and subreceptors that might enhance efficacy or reduce side effects of current alpha-2 compounds. He will be ...

Bad News to Bad Bugs: Northern Antibiotics Develops Novel Polymyxins With Reduced Toxicity

... contain three positive charges only, while polymyxin B and colistin have five. They bind to the isolated brush-border membrane of rat kidney at an affinity which is only 1/5-1/7 of that for polymyxin B. In vivo rat studies also show remarkable differences in parameters that are considered to indicate ...

Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohn's Disease

... About Cimzia(R) (certolizumab pegol) Cimzia(R) is the first and only PEGylated anti-TNFa (Tumor Necrosis Factor alpha). Cimzia(R) has a high affinity for human TNF-alpha, selectively neutralizing the pathophysiological effects of TNF-alpha. Over the past decade, TNF-alpha has emerged as a major ...

Neurocrine Biosciences Reports First Quarter 2008 Results

... (CRF1) Receptor Antagonists for Anxiety/Depression and IBS The CRF collaboration between Neurocrine and GSK has identified multiple unique high affinity and selective antagonists for the CRF1 receptor that are currently in clinical development for mood disorders and irritable bowel syndrome (IBS). ...

Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients

... addition, the binding power of FOSRENOL, in vitro, was not compromised by pH variations throughout the gastrointestinal tract. FOSRENOL has a high affinity for phosphate and works by binding to dietary phosphorus in the gastrointestinal tract. Once bound, the FOSRENOL/phosphorus complex cannot pass into ...

CoAxia(TM) Announces $11.5M Equity Financing From Existing Investors

... additional stroke populations. Canaan Partners and Prism Venture Partners co-led the recent $11.5M financing, with Baird Venture Partners, affinity Capital Management, Johnson and Johnson Development Corporation and SVB Capital Partners also participating as major investors. Brent Ahrens, ...

FDA Accepts Investigational New Drug Application for ARI-2243 and a First in Man Clinical Trial Set to Begin During the First Half of 2008

... active, smart DPP-4 inhibitor that is highly potent and functionally selective. In vitro, kinetic studies show that ARI-2243 has an extremely high affinity (Ki of 27 picomolar) for the DPP-4 enzyme and drug dissociation from the enzyme is very slow. Such kinetics confer potency and long activity. During ...

Independent Data Safety Monitoring Board Recommends Continuation of Sangart's Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review

... transport agent designed to serve as an oxygen therapeutic and as an alternative to blood transfusions. A key property of Hemospan is its high oxygen affinity which results in targeted oxygen delivery to tissues at risk of oxygen deprivation. About Sangart Sangart is a privately held biopharmaceutical ...

NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference

... in Phase 2 clinical trials for cancer. The compound series appears to bind Hsp90 in a different mode than 17AAG or radicicol and exhibit higher affinity to Hsp90 than radicicol. NXD30001 and its analogs efficiently inhibit cell proliferation and deplete multiple Hsp90 client proteins such as Her2, ...

UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies

... Medical Systems LLC and the University of Maryland, Baltimore: Noninvasive Sensing of Glucose and Lactate; $219,974. -- North Potomac-based Potomac affinity Proteins LLC and the University of Maryland Biotechnology Institute: Proteases and Tags for Protein Purification; $135,000. -- Hollywood-based ...

Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results

... which has started a Phase I single escalating dose trial. The CRF collaboration between Neurocrine and GSK has identified multiple unique high affinity and selective antagonists for the CRF1 receptor that are currently in clinical development for mood disorders and IBS. GSK has completed the first ...

Sangart, Inc. Initiates Dosing in Phase II Study of Hemospan(R) in Chronic Critical Limb Ischemia

... transport agent designed to serve as an oxygen therapeutic and as an alternative to blood transfusions. A key property of Hemospan is its high oxygen affinity which results in targeted oxygen delivery to tissues at risk of oxygen deprivation. About Sangart Sangart is a privately held biopharmaceutical ...
Other Contents
(Date:8/27/2014)... Reportlinker.com announces that a new market ... Law Enforcement Biometrics Market in North America ... About Biometrics Biometrics is a technology that ... their physical or behavioral patterns. It involves the ... as fingerprints, face recognition, DNA, palm print, hand ...
(Date:8/27/2014)... easier when it is related to ability that we ... a new melody more easily than learning how to ... Center for the Neural Basis of Cognition (CNBC)a joint ... Universityhave discovered a fundamental constraint in the brain that ... story in the Aug. 28, 2014, issue of ...
(Date:8/27/2014)... Europe based upon a proxy for impact have been ... data, approach to scientific research. , The researchers from ... the top 100 pathogens affecting humans and the top ... believe, will help governments across the continent plan for ... as a result of climate change, and for biosecurity. ...
Breaking Biology News(10 mins):Law Enforcement Biometrics Market in North America 2014-2018 2Law Enforcement Biometrics Market in North America 2014-2018 3Law Enforcement Biometrics Market in North America 2014-2018 4Law Enforcement Biometrics Market in North America 2014-2018 5Pitt and Carnegie Mellon engineers discover why learning can be difficult 2Pitt and Carnegie Mellon engineers discover why learning can be difficult 3Big data approach identifies Europe's most dangerous human and domestic animal pathogens 2
(Date:8/27/2014)... Silver Spring, Md. (PRWEB) August 27, 2014 ... Physicians (CHEST) recently released guidelines for the management ... adults, Pharmacological Therapy for Pulmonary Arterial Hypertension in ... guidelines are free to view for clinicians, and ... for PAH. , The Pulmonary Hypertension Association ...
(Date:8/27/2014)... Dennis Thompson HealthDay ... Someone who has been mugged in a dark alley will ... with a fear of being attacked. But neuroscientists working ... how memories are linked with positive and negative emotions. And ... emotions attached to a memory. In essence, they made ...
(Date:8/27/2014)... Warren, MI (PRWEB) August 27, 2014 Michigan ... to help the children of a local elementary school by ... year. Siersma Elementary School has year-round attendance, and Michigan Head ... equipped to meet the new school year. , "There are ... think this is a great way to give back to ...
(Date:8/27/2014)... August 27, 2014 The federal judge ... ) has extended the deadline for plaintiffs to enroll ... 2014 Order issued by U.S. District Judge David Katz ... enroll in the DePuy ASR Settlement Program must do ... Inc. ASR Hip Implant Products Liability Litigation – MDL ...
(Date:8/27/2014)... (HealthDay News) -- Pouring half a glass of wine at a ... new study. Researchers asked 74 college students and staff to ... that had varying amounts of wine in them. The participants were ... had a "rule of thumb" about how much to pour -- ... from the top -- poured less wine than those without set ...
Breaking Medicine News(10 mins):Health News:Pulmonary Hypertension Association Endorses CHEST Guidelines for Treatment of Pulmonary Arterial Hypertension in Adults 2Health News:Scientists 'Rewrite' Bad Memories in Mice 2Health News:Scientists 'Rewrite' Bad Memories in Mice 3Health News:Michigan Head & Neck Institute is Conducting Their 2nd Annual School Supplies Drive at Their Facility to Benefit Local Year-Round Elementary School Students 2Health News:DePuy ASR Settlement Enrollment Deadline Extended Until September 30, 2014, Bernstein Liebhard LLP Reports 2Health News:DePuy ASR Settlement Enrollment Deadline Extended Until September 30, 2014, Bernstein Liebhard LLP Reports 3Health News:'Half a Glass' Rule May Curb Overdrinking 2
Other TagsOther Tags